Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu • (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.
These molecular insights may foster effective therapies using existing drugs for patients with COVID-19.
This study of ischemic stroke patients is the first to associate the neutrophil-lymphocyte ratio in patients with COVID-19 and ischemic stroke and stroke severity.
These lipids may act as a biomarker for Type 1 diabetes and offer a therapeutic target to prevent the disease.
A drug that inhibits the protease plasmin is hypothesized to reduce the infectivity and virulence of the virus, as measured by reduced need for hospitalization within a week.
These potent CD4+ and CD8+ T-cell responses were stimulated in the lungs following a single intranasal administration.
UAB and Polish researchers propose that the COVID-19 virus acts as a microRNA “sponge” to deplete miRNA levels in ways that aid viral replication and stymie the host immune response.
This is the first comprehensive genomic study of cervical cancers in sub-Saharan Africa, with a focus on tumors from 212 Ugandan patients. The findings can lead to better treatments.
The pilot projects will yield payoffs down the road from the knowledge UAB researchers gain. Preliminary data from the pilots will form the basis for new grants and contracts, including pursuit of the $2 billion COVID-19 grant support being offered by the National Institutes of Health.
A study identifying biomarkers for certain neuroendocrine cancers demonstrates a novel approach for identifying and detecting tumor drivers, giving this diagnostic-therapeutic coupled system a broad translational potential.
The drug candidate is a non-toxic small molecule that given orally effectively rescued mice from models of Type 1 and Type 2 diabetes.